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We present a 55-year-old female patient who underwent burr-hole drainage due to chronic subdural hematoma, with 
obstructive prosthetic aortic valve dysfunction. Anesthetic management of a patient with severe obstructive prosthetic 
aortic valve dysfunction can be challenging. Similar considerations should be given to patients with aortic stenosis with 
an additional emphasis on thrombotic complication due to discontinuation of anticoagulation, which may further jeop-
ardize the valve dysfunction. This case emphasizes the importance of a comprehensive understanding of the etiology and 
hemodynamic consequences of obstructive prosthetic valve dysfunction and the adequacy of anticoagulation for patients 
undergoing noncardiac surgery even after a successful valve replacement. (Korean J Anesthesiol 2014; 66: 160-163)
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Even after a successful heart valve replacement without pros-
thetic valve malfunction, obstructive prosthetic valvular dys-
function (PVD) may occur due to prosthesis-patient mismatch 
(PPM), pannus formation, and thrombus formation [1]. Consid-
ering the relatively narrow anatomic feature of the left ventricu-
lar (LV) outflow tract, the aortic valve is more prone to develop 
PPM after valve replacement [2]. In patients who underwent 
aortic valve replacement due to severe stenosis, the persistence 
of an increased pressure gradient across the aortic valve would 
counteract the favorable reverse remodeling of concentric LV 
hypertrophy, which is well known to be associated with an ad-
verse outcome [3]. Furthermore, in the case of mechanical heart 
valves, discontinuation of anticoagulation for other medico-
surgical conditions may further aggravate the pressure imposed 
on the LV due to thrombus formation [4]. We herein report a 
case of a patient with obstructive PVD after mechanical aortic 
valve replacement for severe aortic stenosis, requiring burr-hole 
drainage for a subdural hematoma.
Case Report
A 55-year-old woman (height 153 cm, weight 59.5 kg) was 
scheduled for burr-hole drainage due to a subdural hematoma. 
Previous medical history revealed rheumatic involvement of 
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heart valves resulting in moderate mitral stenosis and severe aor-
tic stenosis with a preserved LV ejection fraction (EF) of 83%. 
Accordingly, the patient had undergone a double heart valve 
replacement (DVR) surgery 6 years ago with mechanical valves 
(SorinⓇ, Sorin group, Milano, Italy) #18 and #25 for the aortic 
and mitral valve, respectively. Echocardiography performed 
immediately after DVR revealed a LVEF of 60% and significant 
reductions in the peak and mean systolic pressure gradient 
(PSPG/MSPG) across the prosthetic valves. In detail, the PSPG/
MSPG across the aortic valve was reduced from 122/74 mmHg 
to 29/12 mmHg. Follow-up echocardiography performed 2 
years after DVR revealed an increased pressure gradient across 
the prosthetic aortic valve (PSPG/MSPG = 91/57 mmHg) due to 
PPM and possibly from pannus formation, with good motion of 
the prosthetic mitral valve and normal LVEF. Echocardiography 
performed a year ago revealed similar findings with persistence 
of the pressure gradient across the aortic valve (PSPG/MSPG = 
98/50 mmHg) (Fig. 1). While the patient had been asymptom-
atic regarding obstructive PVD, her treatment plan was close 
medical observation.
Warfarin 7.5 mg and olmesartan 10 mg was given orally per 
day after DVR, and warfarin was discontinued as soon as the 
diagnosis of a subdural hematoma was confirmed. The patient’s 
electrocardiography (ECG) showed a sinus rhythm with first-
degree AV block and other preoperative laboratory studies were 
all within the normal limits. As the patient was free of cardiac 
symptoms, an additional echocardiography was not performed 
before the burr-hole drainage.
We planned to perform general anesthesia under the assump-
tion that her hemodynamic status was similar to a patient with 
severe, asymptomatic aortic stenosis. Upon arriving at the op-
erating room, the patient was alert and standard monitoring 
devices were applied including 3-lead ECG, noninvasive blood 
pressure and pulse-oximetry. Initially assessed vital signs were as 
follows: arterial blood pressure of 173/72 mmHg, pulse rate of 63 
beats/min, and peripheral oxygen saturation (SpO2) of 100% in 
room air. Glycopyrrolate 0.1 mg was given as premedication and 
radial artery cannulation under local anesthesia was performed 
for continuous monitoring of arterial blood pressure before an-
esthetic induction. Anesthesia was induced via the intravenous 
route using midazolam 3.5 mg, thiopental sodium 50 mg, and a 
continuous infusion of remifentanil using a target-controlled in-
fusion device (OrchestraⓇ infusion pump system, Fresenius vial, 
Brenzins, France). The effect site concentration of remifentanil 
was gradually increased while paying attention to the patient’s vi-
tal signs. After loss of consciousness, mask ventilation was main-
tained with 1.5 % of sevoflurane in 100% oxygen, and 30 mg of 
rocuronium bromide was injected intravenously. After the effect 
site concentration of remifentanil reached 4.0 ng/ml, the trachea 
was intubated and the lungs were mechanically ventilated with 
60% oxygen with air. Mechanical ventilation was performed to 
achieve an end-tidal carbon dioxide level between 35 and 40 
mmHg. Her heart rate remained unchanged while her blood 
pressure was maintained between 130/70 mmHg and 140/80 
mmHg during the period of anesthetic induction and tracheal 
intubation. For anesthesia maintenance, sevoflurane was careful-
ly titrated to maintain a bispectral index score between 40 and 
60. The effect site concentration of remifentanil was adjusted to 
maintain the intraoperative blood pressure and heart rate within 
20% of the preoperative values. Major hemodynamic goals dur-
ing the surgery were to maintain the systolic blood pressure 
between 130-170 mmHg, diastolic blood pressure between 
60-80 mmHg, and pulse rate between 55-70 beats/min. Upon 
completion of the surgery, sevoflurane was discontinued, and 
the neuromuscular blockade was antagonized with 0.2 mg of 
glycopyrrolate and 1 mg of neostigmine. After confirmation of 
regaining adequate consciousness and spontaneous respiration, 
the patient was transferred to the post anesthesia recovery unit. 
The duration of the surgery and anesthesia was 30 and 60 min, 
respectively, and 200 ml of colloid solution and 300 ml of crys-
talloid solution were given. There were no remarkable events in 
the operating room and in the post anesthesia recovery unit.
Two days after the operation, transthoracic echocardiography 
was performed, and it still showed an increased aortic valvular 
pressure gradient (PSPG/MSPG = 100/55 mmHg), an aortic 
valve area (AVA) of 0.88 cm2 and an indexed effective orifice 
area (EOA) of 0.56 cm2. While warfarin could not be restarted 
immediately, a follow-up transesophageal echocardiography 
was performed on the tenth day after operation, which revealed 
a hyperechogenic fixed structure at right coronary cusp side, 
which seemed to be suspicious of a pannus formation or orga-
nized thrombus (Fig. 2). In addition, good motion of the pros-
thetic aortic valve with flow acceleration, partial motion limita-
Fig. 1. Transthoracic echocardiography conducted a year ago revealed 
an increased pressure gradient through the prosthetic aortic valve (peak/
mean pressure = 98/50 mmHg).
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tion of the anterolateral leaflets of the prosthetic mitral valve, 
and moderate mitral stenosis (mid-diastolic pressure gradient 
= 10 mmHg) probably due to thrombus formation were also 
observed. Despite these findings, warfarin could not be started 
until 2 weeks after the surgery to prevent fatal hemorrhagic 
complications. Heart computer tomography on the eighteenth 
day after the operation showed no significant coronary artery 
disease, no prosthetic mitral valve dysfunction, and a well-
functioning prosthetic aortic valve. Follow-up echocardiography 
performed upon discharge 3 weeks after the operation revealed 
a slightly decreased pressure gradient across the aortic valve 
(PSPG/MSPG = 89/50 mmHg) and a well-functioning pros-
thetic mitral valve with loss of the previously observed pressure 
gradient with a LVEF of 73%. The patient was discharged with-
out any complications.
Discussion
Anesthetic management of a patient with obstructive PVD 
can be challenging. In particular, the obstructive PVD at the 
aortic site has hemodynamic properties similar to aortic stenosis 
such as obstruction of LV ejection, elevated transvalvular pres-
sure gradient and concentric LV hypertrophy [5,6]. The continu-
ous and fixed high-pressure imposed on the LV can interfere with 
the favorable reverse remodeling of the LV hypertrophy normally 
observed after successful valve replacement [7]. Limited regres-
sion of LV hypertrophy is associated with higher long-term mor-
tality and increased risk of complications such as stroke, sudden 
death and recurrent cardiac symptoms [3]. Various causes have 
been identified for the development of obstructive PVD includ-
ing PPM, pannus and/or thrombus formation [1].
PPM was described as elevation of the transvalvular pressure 
gradient generated by the smaller effective area of the inserted 
prosthetic valve compared to that of the native human valve [8]. 
The parameter for measuring the severity of PPM is the EOA 
of the valve which is the EOA of the prosthesis divided by the 
patient’s body surface area (BSA, indexed EOA = EOA/BSA) [2]. 
Pannus formation is an overgrowth of fibrous tissue composed of 
elastic tissue and collagen with chronic inflammatory cells, endo-
thelial cells and myofibroblasts [1]. Although the exact etiology 
is unknown, a variety of factors are involved in its formation. 
Recent reports showed that prosthetic valve dysfunction with 
pannus was related to a significant elevation in the level of trans-
forming growth factor beta 1, which plays an important role in 
the growth and differentiation of cells and matrix formation [5]. 
Thrombus formation is the most common problem with an ap-
proximate incidence of 4% per patient-year and anticoagulation 
reduces the risk to 1% per patient-year [9]. Although challeng-
ing, a differential diagnosis of thrombus from pannus forma-
tion in obstructive PVD is very important in terms of the use of 
thrombolytic therapy [10]. Anticoagulation status, duration of 
symptom, and ultrasound intensity of the lesion causing the ob-
structive PVD can help differentiate thrombus from pannus for-
mation [10]. Generally, the treatment in asymptomatic patients 
with PPM or pannus is regular follow-up without reoperation 
despite the high transvalvular pressure gradient. Thrombus can 
be resolved by adequate anticoagulation and thrombolysis [10]. 
However, thrombolytic therapy cannot be applied in patients at 
a risk of hemorrhagic complications as in this case. 
In the current case, a high-pressure gradient across the pros-
thetic aortic valve corresponding to severe aortic stenosis due to 
PPM and/or pannus formation was observed in the preopera-
tive echocardiography. Thus, anesthetic considerations for the 
noncardiac surgery of patients with severe aortic stenosis were 
applied for this case although this patient was free of cardiac 
symptoms. Notwithstanding the high mortality in patients 
Fig. 2. Transesophageal echocardiography 
on the tenth day after the operation re-
vealed a hyperechogenic fixed structure at 
the right coronary cusp side, which seemed 
to be suspicious of a pannus for mation or 
organized thrombus.
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with severe aortic stenosis undergoing noncardiac surgery (up 
to 15%) [11], this patient had an unremarkable perioperative 
course probably due to the following reasons. Besides being free 
of cardiac symptoms, another reason for the observed favorable 
prognosis was that she did not have severe concentric LV hyper-
trophy (LV mass index = 101 g/m2) even in the presence of se-
vere obstructive PVD [12]. Actually, patients with concentric LV 
hypertrophy suffer from congestive heart failure due to diastolic 
dysfunction despite preserved systolic function. No cardiac 
symptoms and no severe LV hypertrophy in the preoperative 
echocardiography may serve as good prognostic factors in pa-
tients with obstructive PVD undergoing noncardiac surgery.
Although sharing a similar pathophysiology, an additional 
problem that needs to be addressed in patients with obstructive 
PVD in contrast to patients with aortic stenosis is discontinua-
tion of anticoagulation in the presence of other life-threatening 
medico-surgical co-morbidities. Adequate anticoagulation is 
essential to prevent thrombus formation in patients with me-
chanical prosthetic valves. Usually, withholding of anticoagula-
tion in patients with prosthetic heart valves and intracranial 
hemorrhage for less than 7 days was related to low thromboem-
bolic incidence and there was no clinical evidence of prosthetic 
heart valve dysfunction when anticoagulation was stopped for 
less than 14 days [4]. In this case, however, anticoagulation was 
withheld for 4 weeks (2 weeks prior to the surgery upon diag-
nosis confirmation and 2 weeks after the surgery) jeopardizing 
the integrity of the prosthetic valves. Indeed, a newly developed 
increased pressure gradient was observed across the mitral valve 
with some motion limitation indicating the presence of throm-
bus. Fortunately, the pressure gradient and dysfunction of the 
mitral valve were resolved after anticoagulation in the current 
case without affecting the already increased pressure gradient 
across the aortic valve. By considering the risk/benefit ratio of 
anticoagulation therapy in such a patient population, close fol-
low-up and communication with the surgeon and cardiologist 
seem to be an absolute necessity to prevent any mishaps jeopar-
dizing the outcome of patients.
In conclusion, the presence of obstructive prosthetic valve 
dysfunction in a noncardiac surgical setting can be a serious 
challenge to anesthesiologists. When present at the aortic site, 
similar considerations should be given as in patients with aortic 
stenosis with an additional emphasis on thrombotic compli-
cations due to discontinuation of anticoagulation. This case 
emphasizes the importance of a comprehensive understanding 
of the etiology and hemodynamic consequences of obstructive 
PVD and the adequacy of anticoagulation for patients undergo-
ing noncardiac surgery even after a successful valve replace-
ment.
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